基本信息
浏览量:264
职业迁徙
个人简介
Lorenzo Galluzzi (born 1980) is currently Assistant Professor of Cell Biology in Radiation Oncology with the Department of Radiation Oncology of the Weill Cornell Medical College (New York, NY, USA), Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine (New Haven, CT, USA), and Assistant Professor of Cell and Developmental Biology with the Graduate School of Medical Sciences of the Weill Cornell Medical College (New York, NY, USA), as well as Faculty Member with Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara (Ferrara, Italy), the Graduate School of Pharmacological Sciences of the University of Padova (Padova, Italy), and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza” (Rome, Italy).
Prior to joining Weill Cornell Medical College (2017), Lorenzo Galluzzi was a Junior Scientist of the Research Team “Apoptosis, Cancer and Immunity” at the Cordeliers Research Center (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Comprehensive Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the University Paris Sud (Le Kremlin-Bicetre, France; 2005-2008). He is also Associate Director of the European Academy for Tumor Immunology (EATI), and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP).
Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 500 scientific articles in international peer-reviewed journals. According to a survey published by Lab Times, he was the 6th and the youngest of the 30 most-cited European cell biologists (for the period 2007–2013), and he has been nominated Highly Cited Researcher by Clarivate Analytics (formerly, Thomson Reuter) in 2016 (Biology & Biochemistry), 2018 (Cross-Fields), 2019 (Immunology and Molecular Biology & Genetics), 2020 (Immunology and Molecular Biology & Genetics), 2021 (Immunology, Molecular Biology & Genetics and Pharmacology/Toxicity, with only 22 other scientists worldwide, all disciplines confounded) and 2022 (Immunology, Molecular Biology & Genetics and Pharmacology/Toxicity, with only 31 other scientists worldwide, all disciplines confounded).
Lorenzo Galluzzi currently operates as Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell Biology, and Molecular and Cellular Oncology (which he co-founded in 2013). In addition, he currently serves in various Editorial roles for multiple journals including: Cell Death and Disease, iScience, Pharmacological Research, Cell Communication and Signaling, Microbial Cell, Cell Stress and Aging.
Prior to joining Weill Cornell Medical College (2017), Lorenzo Galluzzi was a Junior Scientist of the Research Team “Apoptosis, Cancer and Immunity” at the Cordeliers Research Center (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Comprehensive Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the University Paris Sud (Le Kremlin-Bicetre, France; 2005-2008). He is also Associate Director of the European Academy for Tumor Immunology (EATI), and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP).
Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 500 scientific articles in international peer-reviewed journals. According to a survey published by Lab Times, he was the 6th and the youngest of the 30 most-cited European cell biologists (for the period 2007–2013), and he has been nominated Highly Cited Researcher by Clarivate Analytics (formerly, Thomson Reuter) in 2016 (Biology & Biochemistry), 2018 (Cross-Fields), 2019 (Immunology and Molecular Biology & Genetics), 2020 (Immunology and Molecular Biology & Genetics), 2021 (Immunology, Molecular Biology & Genetics and Pharmacology/Toxicity, with only 22 other scientists worldwide, all disciplines confounded) and 2022 (Immunology, Molecular Biology & Genetics and Pharmacology/Toxicity, with only 31 other scientists worldwide, all disciplines confounded).
Lorenzo Galluzzi currently operates as Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell Biology, and Molecular and Cellular Oncology (which he co-founded in 2013). In addition, he currently serves in various Editorial roles for multiple journals including: Cell Death and Disease, iScience, Pharmacological Research, Cell Communication and Signaling, Microbial Cell, Cell Stress and Aging.
研究兴趣
论文共 655 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer research (2024)
CELL RESEARCHno. 1 (2024): 7-8
Lenka Kasikova,Jana Rakova,Michal Hensler,Tereza Lanickova, Jana Tomankova,Josef Pasulka,Jana Drozenova, Katerina Mojzisova,Anna Fialova,Sarka Vosahlikova,Jan Laco,Ales Ryska,
Nature Communicationsno. 1 (2024): 100640-19
IMMUNOLOGICAL REVIEWSno. 1 (2024): 115-127
Nature reviews. Immunologyno. 7 (2024): 537-537
Cellular & molecular immunologypp.1-3, (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn